Related Experiment Video
Updated: Jan 31, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Adjuvant imatinib therapy for gastrointestinal stromal tumors
Peter W T Pisters1, Chiara Colombo
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA. ppisters@mdanderson.org
Abstract:
Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials.
Related Concept Videos
Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:
Gastrointestinal Motility Disorders
Histology of the Gastrointestinal (GI) Tract
The mucosa is sometimes called a mucous membrane due to its mucus-secreting features. This membrane is composed of epithelium, which directly interacts with ingested substances, and the lamina propria, a layer...
Gene Therapy
Physiology of the Gastrointestinal System I: Ingestion and Propulsion
Physiology of the Gastrointestinal System II: Digestion and Absorption
Digestion begins in the mouth, where food undergoes mechanical breakdown by chewing and combines with saliva. Salivary amylase, an enzyme in saliva, starts the breakdown of starches into maltose. The food then travels down the esophagus to the stomach.
In the stomach, a...

